Oasis Midstream Partners LP is set to release first-quarter 2021 results after the closing bell on Wednesday, May 5. The current Zacks Consensus Estimate for the to-be-reported quarter is a profit of 99 cents per share on revenues of $77.6 million. Let’s delve into the factors that might have influenced the diversified energy pipeline partnership’s performance in the March quarter. But it’s worth taking a look at Oasis Midstream’s previous-quarter performance first. Highlights of Q4 Earnings & Surprise History
In the last-reported quarter, the Houston, TX-based energy infrastructure provider beat the consensus mark on the back of strong third-party volumes and efficient cost control. Oasis Midstream reported earnings per unit of $1.61, significantly above the Zacks Consensus Estimate of 67 cents. Moreover, the partnership’s quarterly revenues of $90.6 million beat the Zacks Consensus Estimate by 13%.
As far as earnings surprises are concerned, Oasis Midstream beat the Zacks Consensus Estimate in three of the last four quarters and missed in the other, delivering an earnings surprise of 60.94%, on average. This is depicted in the graph below: Factors to Consider This Quarter
While pipeline entities like Oasis Midstream have a lower correlation to oil and gas prices compared to its peers, this energy sub-industry hasn’t been immune to the coronavirus-induced downturn. With upstream operators pulling back activities and curtailing production in response to last year’s sharply lower commodity pricing and demand, Oasis Midstream faces a potential decline in volumes through its facilities, contributing to expectations for lower profits. As it is, the partnership’s sponsor
Oasis Petroleum ( OAS Quick Quote OAS - Free Report) shut in wells and pulled back capital spending in response to the weakness in commodity prices. Investors should know that Oasis Midstream was formed to primarily serve the midstream operations of Oasis Petroleum. Therefore, any production curtailment on the part of Oasis Petroleum will have impacted its first-quarter results. However, as a counter to these negatives, Oasis Midstream has also done a fairly admirable job at reducing costs. Oasis Midstream’s cash outflows as capital expenditure continue to fall as it reins in the spending levels. Apart from significant capital cuts, the partnership should realize sizeable savings from judicious contractor management and optimization of gathering systems. All this is expected to have pushed Oasis Midstream’s first-quarter earnings and cash flows higher. What Does Our Model Say?
The proven Zacks model does not conclusively show that Oasis Midstream is likely to beat estimates in the first quarter. The combination of a positive
Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of beating estimates. But that’s not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter. Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, for this company is -15.15%. Zacks Rank: Oasis Midstream currently carries a Zacks Rank #1. You can see . the complete list of today’s Zacks #1 Rank stocks here Stocks to Consider
While an earnings beat looks uncertain for Oasis Midstream, here are some firms from the
energy space that you may want to consider on the basis of our model: Whiting Petroleum Corporation ( WLL Quick Quote WLL - Free Report) has an Earnings ESP of +7.27% and a Zacks Rank #1. The firm is scheduled to release earnings on May 5. TC Energy Corporation ( TRP Quick Quote TRP - Free Report) has an Earnings ESP of +2.67% and a Zacks Rank #3. The firm is scheduled to release earnings on May 7. Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better. See these 7 breakthrough stocks now>>